rss
J Neurol Neurosurg Psychiatry 2003;74:1294-1298 doi:10.1136/jnnp.74.9.1294
  • Paper

Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension

  1. W Singer1,
  2. T L Opfer-Gehrking1,
  3. B R McPhee1,
  4. M J Hilz3,
  5. A E Bharucha2,
  6. P A Low1
  1. 1Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
  2. 2Department of Gastroenterology, Mayo Clinic
  3. 3Department of Neurology, University of Erlangen-Nuremberg, Germany
  1. Correspondence to:
 Dr Phillip A Low, Department of Neurology, Mayo Clinic, 811 Guggenheim, 200 First Street SW, Rochester, MN 55905, USA; 
 low{at}mayo.edu
  • Received 5 August 2002
  • Accepted 9 March 2003
  • Revised 29 January 2003

Abstract

Background: Pharmacological treatment of orthostatic hypotension is often limited because of troublesome supine hypertension.

Objective: To investigate a novel approach to treatment using acetylcholinesterase inhibition, based on the theory that enhanced sympathetic ganglion transmission increases systemic resistance in proportion to orthostatic needs.

Design: Prospective open label single dose trial.

Material: 15 patients with neurogenic orthostatic hypotension caused by: multiple system atrophy (n = 7), Parkinson’s disease (n = 3), diabetic neuropathy (n = 1), amyloid neuropathy (n = 1), and idiopathic autonomic neuropathy (n = 3).

Methods: Heart rate, blood pressure, peripheral resistance index (PRI), cardiac index, stroke index, and end diastolic index were monitored continuously during supine rest and head up tilt before and one hour after an oral dose of 60 mg pyridostigmine.

Results: There was only a modest non-significant increase in supine blood pressure and PRI. In contrast, acetylcholinesterase inhibition significantly increased orthostatic blood pressure and PRI and reduced the fall in blood pressure during head up tilt. Orthostatic heart rate was reduced after the treatment. The improvement in orthostatic blood pressure was associated with a significant improvement in orthostatic symptoms.

Conclusions: Acetylcholinesterase inhibition appears effective in the treatment of neurogenic orthostatic hypotension. Orthostatic symptoms and orthostatic blood pressure are improved, with only modest effects in the supine position. This novel approach may form an alternative or supplemental tool in the treatment of orthostatic hypotension, specially for patients with a high supine blood pressure.

Footnotes

  • Competing interests: none declared

  • See Editorial Commentary, p 1187

Responses to this article

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest neurology and neurosurgery jobs